ATE443070T1 - Metallkomplexe mit vitamin b12 als ligand - Google Patents

Metallkomplexe mit vitamin b12 als ligand

Info

Publication number
ATE443070T1
ATE443070T1 AT05706857T AT05706857T ATE443070T1 AT E443070 T1 ATE443070 T1 AT E443070T1 AT 05706857 T AT05706857 T AT 05706857T AT 05706857 T AT05706857 T AT 05706857T AT E443070 T1 ATE443070 T1 AT E443070T1
Authority
AT
Austria
Prior art keywords
vitamin
ligand
metal complexes
cyanide
complex
Prior art date
Application number
AT05706857T
Other languages
English (en)
Inventor
Roger Alberto
Castro Hector Knight
Stefan Mundwiler
Susanne Kunze
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of ATE443070T1 publication Critical patent/ATE443070T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT05706857T 2004-01-08 2005-01-10 Metallkomplexe mit vitamin b12 als ligand ATE443070T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04075003 2004-01-08
EP04077937 2004-10-25
PCT/EP2005/000168 WO2005068483A1 (en) 2004-01-08 2005-01-10 Metal complexes having vitamin b12 as a ligand

Publications (1)

Publication Number Publication Date
ATE443070T1 true ATE443070T1 (de) 2009-10-15

Family

ID=34796701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05706857T ATE443070T1 (de) 2004-01-08 2005-01-10 Metallkomplexe mit vitamin b12 als ligand

Country Status (12)

Country Link
US (1) US7692002B2 (de)
EP (1) EP1704157B1 (de)
JP (1) JP2007518727A (de)
KR (1) KR20070010119A (de)
AT (1) ATE443070T1 (de)
AU (1) AU2005205126A1 (de)
BR (1) BRPI0506740A (de)
CA (1) CA2552916C (de)
DE (1) DE602005016648D1 (de)
ES (1) ES2334923T3 (de)
IL (1) IL176664A (de)
WO (1) WO2005068483A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101019555B (zh) * 2007-03-23 2011-03-30 南京师范大学 稀土-氨基酸-维生素三元配合物植物生长调节剂及其制备方法
CA2792319A1 (en) * 2010-03-08 2011-09-15 University Of Zuerich Carbon monoxide releasing rhenium compounds for medical use
SG10202103336SA (en) 2010-11-02 2021-04-29 Promega Corp Novel coelenterazine substrates and methods of use
WO2012061477A1 (en) 2010-11-02 2012-05-10 Promega Corporation Coelenterazine derivatives and methods of using same
US9385033B2 (en) * 2013-09-27 2016-07-05 Intel Corporation Method of forming a metal from a cobalt metal precursor
JP6588917B2 (ja) 2014-01-29 2019-10-09 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 生細胞への適用のためのプロ基質
WO2015116867A1 (en) 2014-01-29 2015-08-06 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560782A (en) * 1982-11-19 1985-12-24 Research Corporation Anti-tumor diplatinum coordination compounds
US4673631A (en) * 1984-12-15 1987-06-16 Canon Kabushiki Kaisha Toner, charge-imparting material and composition containing metal complex
EP0415963A1 (de) * 1988-05-09 1991-03-13 Microbiological Research Authority Verwendung von metallchelatkomplexen bei der halogenierung
US5393909A (en) * 1988-11-22 1995-02-28 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
GB8910760D0 (en) * 1989-05-10 1989-06-28 Health Lab Service Board Corrin mediated degradation of organic nitrogen compounds
DE19712388A1 (de) * 1997-03-25 1998-10-01 Studiengesellschaft Kohle Mbh Verfahren zur Synthese von aromatisch substituierten Olefinen
US6844425B1 (en) * 1999-02-24 2005-01-18 Mallinckrodt Inc. Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy
US6797521B2 (en) 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
US6180087B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Tunable indocyanine dyes for biomedical applications
US6180085B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Dyes
EP2289508A1 (de) * 2001-01-30 2011-03-02 Dainippon Sumitomo Pharma Co., Ltd. Kombinierte Behandlung für Lungenkrebs
WO2004022105A2 (en) * 2002-09-03 2004-03-18 University Of Zurich Preparation of m(co)3-complexes by solid phase techniques via metal assisted cleavage from the solid support

Also Published As

Publication number Publication date
WO2005068483A1 (en) 2005-07-28
EP1704157A1 (de) 2006-09-27
IL176664A (en) 2013-05-30
DE602005016648D1 (de) 2009-10-29
AU2005205126A1 (en) 2005-07-28
CA2552916C (en) 2014-11-18
BRPI0506740A (pt) 2007-05-15
KR20070010119A (ko) 2007-01-22
EP1704157B1 (de) 2009-09-16
US20090175775A1 (en) 2009-07-09
JP2007518727A (ja) 2007-07-12
IL176664A0 (en) 2006-10-31
ES2334923T3 (es) 2010-03-17
CA2552916A1 (en) 2005-07-28
US7692002B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
ATE443070T1 (de) Metallkomplexe mit vitamin b12 als ligand
Casas et al. A gold (I) complex with a vitamin K3 derivative: characterization and antitumoral activity
MX2008011107A (es) Catalizadores de metal de transicion fluorados y formacion de los mismos.
ATE503746T1 (de) Neue imidazolidinderivate
DK1561754T3 (da) Fremgangsmåde til fremstilling af 1,2-diaminocyclohexanplatin(II)-komplekser
DK1404377T3 (da) Forbedrede chelatorkonjugater
Zayed et al. Preparation and structure investigation of novel Schiff bases using spectroscopic, thermal analyses and molecular orbital calculations and studying their biological activities
DK1079832T3 (da) Anvendelse af vitamin-PP-forbindelser
NZ592400A (en) Transition metal complexes of bis[thiohydrazide amide] compounds
Ye et al. Syntheses, characterizations and biological activities of two Cu (II) complexes with acylhydrazone ligand bearing pyrrole unit
TW200611689A (en) Cancer chemotherapy
TW200706245A (en) Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions
IL174642A0 (en) A process for the preparation of adapalene
DK1789427T3 (da) Fremstilling af platin(II)-komplekser
TW200740835A (en) Transition metal complexes and preparation methods thereof
ATE471331T1 (de) Neue übergangsmetall-komplexe und deren einsatz in übergangsmetall-katalysierten reaktionen
WO2009010129A8 (de) Bispidonliganden und deren metallkomplexe
ATE530557T1 (de) Diphosphinliganden
Thota et al. Synthesis, characterization, antitumor, and cytotoxic activity of mononuclear Ru (II) complexes
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
NO20055334L (no) Bifunksjonelle tridentate pyrazolylinneholdende ligander for RE og TC trikarbonylkomplekser
TW200730473A (en) Process for the production of biphenyls
DE602004027737D1 (de) Neue chemilumineszenzverbindungen und ihre verwendung
ATE556045T1 (de) Tame-basierte chelatoren und ihre anwendungen
Pershin et al. TRANSITION METAL-FREE C–H-AZOLATION OF PHENANTHRIDINE IN THE LIGAND SYNTHESIS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties